SCHEMBL747904

SCHEMBL747904

COc1cccc(OC)c1C1SCC(=O)N1Cc1ccc2c(c1)OCO2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 4/20 0.66
HCRTR2 O43614 4/20 0.66
MGAM O43451 1/20 0.57
TDP1 Q9NUW8 3/20 0.50
ACHE P22303 1/20 0.49
MAPK1 P28482 1/20 0.48
MAPT P10636 2/20 0.47
CMA1 P23946 1/20 0.47
GLA P06280 1/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 3/20 0.47
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL746667 0.94 HCRTR2 (0.60) HCRTR1HCRTR2MGAMTDP1ACHE
SCHEMBL5152300 0.90 HCRTR1 (0.56) HCRTR1HCRTR2MGAMTDP1MAPK1
SCHEMBL745939 0.85 HCRTR2 (0.68) HCRTR1HCRTR2ALDH1A1CYP3A4MEN1
SCHEMBL746869 0.85 HCRTR2 (0.57) HCRTR1HCRTR2SMN1; SMN2CYP3A4MEN1
SCHEMBL746031 0.84 HCRTR2 (0.67) HCRTR1HCRTR2TDP1MAPK1MAPT
SCHEMBL745503 0.82 HCRTR1 (0.65) HCRTR1HCRTR2ALDH1A1MEN1KMT2A
SCHEMBL744347 0.82 HCRTR1 (0.68) HCRTR1HCRTR2CMA1ALDH1A1MEN1
SCHEMBL747775 0.82 HCRTR2 (0.73) HCRTR1HCRTR2ALDH1A1SMN1; SMN2CYP2C9
SCHEMBL744913 0.81 HCRTR1 (0.67) HCRTR1HCRTR2ALDH1A1MEN1KMT2A
SCHEMBL747918 0.81 HCRTR2 (0.67) HCRTR1HCRTR2MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088759-A1 THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-12 US claimed
EP-2429523-A1 THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-03-21 EP claimed
WO-2010131191-A1 THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-11-18 WO claimed
US-20120088759-A1 THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-04-12 US disclosed
EP-2429523-A1 THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-03-21 EP disclosed
WO-2010131191-A1 THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088759-A1 THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, NPY4R HCRTR1 1/4885HCRTR2 2/4885MGAM 4631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.